Drug-resistant TB: latest news

Drug-resistant TB features

Drug-resistant TB news from aidsmap

  • Three-drug regimen beats XDR-TB in first trial

    A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Dr Francesca Conradie of Sizwe Tropical Disease Hospital, ...

    17 February 2017 | Keith Alcorn
  • Shortened regimen for MDR-TB shows good results for children

    The use of the shortened 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB), known as the ‘Bangladesh regimen’ has shown to be successful in 83% of children and adolescents diagnosed with rifampicin-resistant (RR) TB. The findings were presented at TB2016, a ...

    18 July 2016 | Lesley Odendal
  • South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains

    A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB) has concluded that transmission – in both hospitals and households – has been the primary ...

    04 March 2016 | Theo Smart
  • Empirical TB treatment comes up short again

    A South African trial has found that a strategy allowing primary care nurses to quickly provide empirical tuberculosis (TB) treatment for newly diagnosed people with advanced HIV disease at very high risk of, but without confirmed, TB did not ...

    26 February 2016 | Theo Smart
  • MDR-TB treatment: Six drugs better than five

    A regimen containing six drugs was more likely to cure multi-drug resistant tuberculosis (MDR-TB) than a regimen containing five drugs, a nine-country observational study has shown. The study also found that each active drug in the ...

    13 January 2016 | Keith Alcorn
  • Xpert MTB/RIF testing has reduced MDR-TB treatment delays in South Africa

    Although the introduction of the Xpert MTB/RIF test for TB and drug-resistant TB has improved the time from clinic presentation to second-line treatment in South Africa since 2011, improved access to treatment and a reduction in delays of treatment ...

    07 January 2016 | Lesley Odendal
  • One in eight children with confirmed TB have drug-resistant TB in Cape Town

    One in eight children with confirmed TB have drug-resistant TB in Cape Town, South Africa, according to a surveillance study of childhood TB drug-resistance, presented by Professor Simon Schaaf at the 46th Union World Conference on Lung Health held ...

    05 January 2016 | Lesley Odendal
  • Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients

    People living with HIV, those who are underweight and those with more extensive drug resistance are more likely to die during treatment for multi-drug resistant tuberculosis (MDR-TB), a nine-country study has found. The findings were presented at the 46th ...

    10 December 2015 | Keith Alcorn
  • 9-month MDR-TB regimen cures 82% in African study

    A 9-month standardised treatment regimen for multi-drug resistant tuberculosis (MDR-TB) cured 82% of people recruited to an observational study in Francophone Africa, the 46th Union World Conference on Lung Health heard on Saturday in Cape Town. The regimen showed similar ...

    07 December 2015 | Keith Alcorn
  • Newest MDR-TB drug prices could fall by up to 95% through generic production

    The cost of newer drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) could be cut by up to 95% if generic production of patented products could be achieved in the same way as for antiretroviral drugs, according to ...

    22 October 2015 | Keith Alcorn
More news

Drug-resistant TB news selected from other sources

  • Multidrug-resistant tuberculosis in migrants, multi-country cluster

    A multi-country cluster of multidrug-resistant tuberculosis (MDR TB) involving 28 migrants has been delineated by whole genome sequencing (WGS) in migrants recently having arrived from countries in the Horn of Africa. Although the number of cases detected so far is small, there is a possibility that more cases associated with this cluster may still be identified.

    14 April 2017 | ECDC
  • Tuberculosis: Fewer than five per cent of people in need are treated with new drugs

    Outside of a small number of clinical trials and compassionate use programmes, only 469 people received delamanid in 2016, while just over 4,300 received bedaquiline. All other people receiving DR-TB treatment continue instead to be treated with older, more toxic regimens that cure only 50 per cent of people treated, and cause severe side-effects, ranging from deafness to psychosis.

    27 March 2017 | Médecins Sans Frontières (MSF) International
  • TB Alliance Sublicenses Promising Anti-tuberculosis Drug from the Medicines Patent Pool

    On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP's license for the treatment signed with patent holder The Johns Hopkins University in January.

    24 March 2017 | Yahoo Finance
  • New Tuberculosis Drugs May Become Ineffective: Study

    New antibiotics that could treat tuberculosis may rapidly become ineffective, according to new research published by the Lancet ahead of World Tuberculosis Day. The rise in multi-drug resistant tuberculosis, which affected 480,000 people in 2015, could mean that even newly discovered drugs will soon be useless, the study found.

    24 March 2017 | Inter Press Service
  • Rise of superbug tuberculosis hampers global control efforts

    Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.

    23 March 2017 | Reuters
  • TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?

    While the unveiling of a list highlighting the need to fund drug development against specific pathogens represented just a beginning for some antimicrobial resistance fighting efforts, the list represented a setback for TB drug development, advocates say.

    02 March 2017 | Science Speaks
  • New tuberculosis therapy could be more potent than current treatments

    Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.

    26 January 2017 | UCLA
  • Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

    While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.

    26 January 2017 | MSF Access Campaign
  • The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

    The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients.

    25 January 2017 | Medicines Patent Pool
  • Indian Woman Wins Right to Use Last-Resort Tuberculosis Drug

    An 18-year-old woman and her family have won a battle in an Indian court to gain access to a restricted tuberculosis drug that her doctors say she needs to survive.

    24 January 2017 | Wall Street Journal (blog)
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.